IL322689A - הרכבים ושיטות לשימוש באפלורניטין - Google Patents

הרכבים ושיטות לשימוש באפלורניטין

Info

Publication number
IL322689A
IL322689A IL322689A IL32268925A IL322689A IL 322689 A IL322689 A IL 322689A IL 322689 A IL322689 A IL 322689A IL 32268925 A IL32268925 A IL 32268925A IL 322689 A IL322689 A IL 322689A
Authority
IL
Israel
Prior art keywords
regimen
subject
salt
temozolomide
eflornithine
Prior art date
Application number
IL322689A
Other languages
English (en)
Original Assignee
Orbus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbus Therapeutics Inc filed Critical Orbus Therapeutics Inc
Publication of IL322689A publication Critical patent/IL322689A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL322689A 2023-02-17 2024-02-16 הרכבים ושיטות לשימוש באפלורניטין IL322689A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363446495P 2023-02-17 2023-02-17
PCT/US2024/016110 WO2024173768A1 (en) 2023-02-17 2024-02-16 Compositions and methods of using eflornithine

Publications (1)

Publication Number Publication Date
IL322689A true IL322689A (he) 2025-10-01

Family

ID=92420769

Family Applications (1)

Application Number Title Priority Date Filing Date
IL322689A IL322689A (he) 2023-02-17 2024-02-16 הרכבים ושיטות לשימוש באפלורניטין

Country Status (7)

Country Link
EP (1) EP4665325A1 (he)
JP (1) JP2026506073A (he)
KR (1) KR20250172562A (he)
AU (1) AU2024223940A1 (he)
IL (1) IL322689A (he)
MX (1) MX2025009584A (he)
WO (1) WO2024173768A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170273926A1 (en) * 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
ES3058652T3 (en) * 2016-10-06 2026-03-12 Orbus Therapeutics Inc Formulations for administration of eflornithine

Also Published As

Publication number Publication date
MX2025009584A (es) 2025-12-01
JP2026506073A (ja) 2026-02-20
KR20250172562A (ko) 2025-12-09
AU2024223940A1 (en) 2025-08-21
WO2024173768A1 (en) 2024-08-22
EP4665325A1 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
EP2785349B2 (en) Combination treatment of cancer
CN105705148B (zh) 使用普那布林和紫杉烷的组合的癌症疗法
TWI914232B (zh) 用阿曲生坦(ATRASENTAN)治療IgA腎病的方法
JP2021535908A (ja) 鎌状赤血球症を処置するためのｐｄｅ９阻害剤
US10098880B2 (en) Combination of nelfinavir, metformin and rosuvastatin for treating cancer caused by aberrations in PTEN/TP53
US20210338648A1 (en) Methods and compositions for reducing serum uric acid
TW201701880A (zh) 改善持續釋放藥物治療之藥物動力學及治療指數之方法
KR20080110755A (ko) 항암 용도를 위한 독소루비신 제형
CN117257782B (zh) 美利曲辛在逆转奥希替尼耐药中的应用
WO2024173768A1 (en) Compositions and methods of using eflornithine
JP6462582B2 (ja) がんの治療のための方法および組成物
JP2022527630A (ja) 鎌状赤血球症を治療するためのｐｄｅ９阻害剤
US20110251134A1 (en) Combination of (a) a dna toposomerase inhibitor and (b) an iap inhibitor
CA3051828A1 (en) Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
EP4313059A1 (en) A pi3k-delta inhibitor for the treatment of pancreatic cancer
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
JP2008514721A (ja) 治療方法
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
US7906515B2 (en) Cancer treatment with topoisomerase-II inhibitor, a bis-dioxypiperazine and radiation
WO2026057047A1 (en) Methods of treating glioma
RU2784869C1 (ru) Чиаураниб для лечения мелкоклеточного рака легкого
JP2013521229A (ja) 脳腫瘍を処置するための方法
WO2024220839A1 (en) Methods of treating hepatic-only metastatic uveal melanoma
TW202434219A (zh) 使用乏氧激活化合物治療對parp抑制劑耐藥的患者的藥物及其製藥用途
CN114533872B (zh) 靶向cd24的胃癌治疗方法